Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Worth a read
'Political support is building for regulators in the United States to embrace the controversial strategy of intentionally infecting volunteers with the virus that causes COVID-19 in order to test experimental vaccines. Such human challenge trials could greatly accelerate the development of an effective vaccine, 35 members of the House of Representatives argue in a letter sent yesterday to the heads of the U.S. Food and Drug Administration (FDA) and its parent agency, the Department of Health and Human Services (HHS).
“[A] more risk-tolerant development process is likely appropriate in the case of a COVID-19 vaccine,” write the group of lawmakers, which includes both Democrats and Republicans. “The enormous human cost of the COVID-19 epidemic alters the optimization of the risk/benefit analysis.”
https://www.sciencemag.org/news/2020/04/united-states-should-allow-volunteers-be-infected-coronavirus-test-vaccines-lawmakers#
I also remember reading this article back in December. You have Dr Fauci whom we see regularly on the rostrum with Trump saying;
“The vaccine is the gold standard,” says Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases
Yes, there is a race on, but it has been somewhat difficult to get Pharma on board perhaps in the past. However, things have now changed politically (at the very least), what with COVID-19. I would hope that a good competitive and highly viable 'Flu-V' option, is very much in the reckoning for development now though. The economic costs and potential lives that could be lost is too much risk again. Everything ¥, £, $ etc.. should be thrown at best in class vaccine development options - 'Flu-V' being one.
Just as the article ends;
According to the World Bank, a severe outbreak of flu could kill 71 million people and cost the global economy $3 trillion.
Dr Osterholm says this makes for an “extremely powerful incentive” for investing in a new flu vaccine, which while expensive, would cost far less than $3 trillion.
https://www.telegraph.co.uk/global-health/science-and-disease/pandemic-clock-ticking-race-against-time-universal-flu-vaccine/amp/
I would not agree with that statement. Here is a list of current (within the last week) Vaccine developments in the offing. Also, only today GSK and Sanofi made a big partnering announcement to work on developing a vaccine.
* CEPI and GSK will collaborate to help the global effort to develop a vaccine for the novel coronavirus. GSK is making its adjuvant technology available to support rapid development of candidate vaccines and is working with The University of Queensland, Australia.
* CSL Limited partnered with the University of Queensland’s COVID-19 vaccine development program. They will provide technical expertise as well as a donation of Seqirus’ proprietary adjuvant technology to their pre-clinical development program.
* GSK and Sanofi have joined forced to combine innovative technologies to develop an adjuvanted COVID-19 vaccine, which is expected to enter clinical trials in the second half of 2020 and, if successful and subject to regulatory considerations, aim to complete the development required for availability by the second half of 2021.
* Johnson & Johnson expanded its collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of U.S. Department of Health & Human Services (HHS) and established a new collaboration with Beth Israel Deaconess Medical Center (BIDMC) to accelerate development of a potential novel coronavirus vaccine.
* Pfizer and BioNTech have entered into a partnership to jointly develop BioNTech’s mRNA-based vaccine candidate to prevent COVID-19 infection. The collaboration aims to accelerate global development which is expected to enter clinical testing by the end of April 2020.
* Crescent Pharma Limited (UK) is working to develop a vaccine from chloroquine phosphate, which is being used in 10 COVID-19 trials in China.
* GSK announced it would partner with the Chinese biotech company Clover Biopharmaceuticals. Under the partnership, GSK will provide Clover with its proposal.
* Johnson & Johnson announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA); and the rapid scaling of the Company’s manufacturing capacity with the goal of providing global supply of more than one billion doses of a vaccine.
* Sanofi announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), to advance a novel COVID-19 vaccine candidate.
https://novuscomms.com/2020/03/31/a-view-from-the-hvivo-open-orphan-orph-laboratory-professor-john-oxford/
Prof John Oxford;
"Finally, I am pleased that hVivo/Open Orphan is out there looking for good contracts with COVID, RSV and Influenza. In the long term all 3 viruses are important and the quarantine and laboratory expertise is key to the future. COVID will probably settle down or as a yearly disease like flu."
Tweet from Trump from today.
'General Motors MUST immediately open their stupidly abandoned Lordstown plant in Ohio, or some other plant, and START MAKING VENTILATORS, NOW!!!!!! FORD, GET GOING ON VENTILATORS, FAST!!!!!! @GeneralMotors @Ford'
Some context in news;
'US President Donald Trump attacked the General Motors company on Friday for not producing new ventilators, demanding they “start making ventilators now” in a tweet.
“They said they were going to give us 40,000 much needed Ventilators, ‘very quickly’ Now they are saying it will only be 6,000, in late April, and they want top dollar,” the president tweeted, suggesting he would invoke the Defense Production Act, which allows the federal government to direct industries.'
Summary of NIAID Flu-v Trial results
'The results of this study were consistent with what was observed in previous phase I trials and a recently conducted phase IIb trial in the field carried out in the Netherlands38. In this 175-
participant study, one dose of adjuvanted FLU-v was shown to be safe and to induce long-lasting cell-mediated immune responses.
This study demonstrated that the T cell strategy employed by FLU-v has potential to offer protection against influenza infection
as a vaccine. These results demonstrate that T cell immunity against conserved regions of the influenza virus is likely to be an important component for “universal” vaccine strategies. Larger studies with FLU-v can further describe the cellular immune response and evaluate how the vaccine interacts with influenza disease in different cohorts, allowing for informed clinical
development of FLU-v and other vaccine strategies that induce T cell immunity.
The need for better, more broadly protective vaccines against influenza is a high priority worldwide, and few new vaccines have
demonstrated efficacy in humans. The efficacy of FLU-v in this wild-type human influenza challenge study along with the supporting data from previous trials in the field should be further
examined in larger field trials where efficacy of FLU-v will be evaluated against a broader set of influenza strains and wider spectrum of disease to determine if these results will be broadly applicable.'
https://www.wired.com/story/self-driving-cars-ces-semi-autonomous-veoneer/
.@seeingmachines is pleased to announce a signed agreement w First Bus, one of the UK’s leading bus operators, to deploy our Guardian driver monitoring tech to numerous bus services across the UK & Ireland: https://t.co/bezKLtjRyR #seeingmachines #SEEGuardian #DMS @FirstBusnews
Sorry, looks like LSE does not like website links with Japanese calligraphy in the address.
Try this shortened bitly.com short conversion instead. Hope it works.
https://bit.ly/2zIzB2j
Assuming you use a browser with Auto translation features. Still not a great translation using Chrome, but basically
'Mecty' announced today they will be exhibiting at 'Automotive World - Japan" on Weds 16 Jan 2019. One of the companies exhibiting jointly with them is Seeing Machines.
http://www.nexty-ele.com/news/detail/???????????????(????japan)/
https://www.proactiveinvestors.co.uk/companies/amp/media_files/11333?__twitter_impression=true
https://twitter.com/seeingmachines/status/1065681607984594946?s=19
A question posed too and then answered by Safestocks this morning:
EvilGenious on 19th November 2018 at 8:40 am said:
In one week Smart Eye has won 6 DW’s with two existing customers (BMW and Audi?) Would you care to comment on that?
Reply ↓
Admin/Safestocks on 19th November 2018 at 9:21 am said:
Hi Erik,
I notice the win is for 2019-20 models so clearly being rushed out as an extension to the existing deals on the same platform. A camera DMS is better than no camera DMS, clearly. Let me ask you a question: don’t you think that it strange that for Mercedes and BMW Seeing Machines has won huge contracts for vehicles coming 2020 and beyond? I personally would be surprised if Audi opt for SmartEye in vehicles coming after 2020. The reason is simple: according to all my sources Seeing Machines has the best tech.
You can play this Podcast using your browser without downloading 'Soundcloud'. Steven Flecther VP Business Development 'Seeing Machines' - partial or full presentation he did at the 'Truck Australia Tech & Maintenance' conference last month. Note the Privacy question asked at the end at least.
All this starts at 17mins 40secs mark, so fast forward on a bit.
https://m.bigrigs.com.au/news/do-you-think-you-need-more-room-sleep/3570943/
https://www.fullyloaded.com.au/industry-news/1811/toll-unveils-new-transport-control-room
"Toll says its control room is part of its broader eight-year $1.6 billion investment in new fleet and equipment. "
Hope SEE get a big chunk of that investment ;-D
Are we working with Visteon ?
https://www.prnewswire.com/news-releases/visteon-showcases-cockpit-electronics-technology-to-support-electric-vehicles-at-evs31-in-japan-300721506.html
At EVS31, Visteon will display products including:
"A 4K instrument cluster with integrated driver monitoring infrared cameras for facial recognition and head and eye-gaze tracking, which will be important to assessing driver readiness to resume control of an automated vehicle."
Anyone susbscribe to 'The Australian' ?
Article dated today with Mike Lenne smiling above said article.
https://amp.theaustralian.com.au/life/motoring/driver-response-time-doubles-with-autopilot/news-story/3a0b397ecce7e24cc7c85995fd5a8d83
Best guess six T1s evaluating @seeingmachines Fovio DMS: Aptiv, Denso, Hyundai Mobis, Valeo, Visteon, ZF. Each month means more data gathered by Guardian (>100m kms/mo ?) = more training & refinement for SM DMS algos. Delays & longer evals. by OEMs/T1s thus seems to favor SM.